|
|
Volumn 1, Issue 6, 2002, Pages 413-414
|
|
Drugs that target angiogenesis. Market indicators
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID;
AE 941;
ANGIOGENESIS INHIBITOR;
ANGIOSTATIN;
ANTINEOPLASTIC AGENT;
BASIC FIBROBLAST GROWTH FACTOR;
BECAPLERMIN;
BEVACIZUMAB;
CANCER VACCINE;
CELECOXIB;
CYCLOOXYGENASE 2 INHIBITOR;
CYTOKINE;
CYTOSTATIC AGENT;
ENDOSTATIN;
MARIMASTAT;
MATRIX METALLOPROTEINASE INHIBITOR;
MONOCLONAL ANTIBODY;
PEPTIDE DERIVATIVE;
PLATELET DERIVED GROWTH FACTOR;
PRINOMASTAT;
PROTEINASE INHIBITOR;
RIBOZYME;
SEMAXANIB;
SQUALAMINE;
TANOMASTAT;
THALIDOMIDE;
VASCULOTROPIN;
VASCULOTROPIN INHIBITOR;
ANGIOGENESIS;
CANCER CHEMOTHERAPY;
CANCER INCIDENCE;
CANCER MORTALITY;
CELL PROLIFERATION;
CLINICAL TRIAL;
COLON CANCER;
DIABETIC FOOT;
DRUG APPROVAL;
DRUG COST;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG MECHANISM;
DRUG TARGETING;
GENE THERAPY;
HEALTH CARE COST;
HUMAN;
MEDICAL RESEARCH;
MORBIDITY;
NATIONAL HEALTH SERVICE;
NOTE;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
PSORIASIS;
SIDE EFFECT;
TREATMENT FAILURE;
ARTICLE;
NEOPLASM;
ANGIOGENESIS INHIBITORS;
HUMANS;
NEOPLASMS;
|
|
EID: 0036595259
PISSN: 14741776
EISSN: None
Source Type: Journal
DOI: 10.1038/nrd824 Document Type: Note |
|
Times cited : (18)
|
|
References (0)
|
